<DOC>
	<DOCNO>NCT00402805</DOCNO>
	<brief_summary>The purpose study test specific humoral response intramuscular intradermal influenza vaccination lung transplant recipient</brief_summary>
	<brief_title>Improving Humoral Response Influenza Vaccine Lung Transplant Recipients Intradermal Strategy</brief_title>
	<detailed_description>Influenza virus important cause morbidity lung transplant population lead viral bacterial pneumonia contribute bronchiolitis obliterans syndrome . Although annual influenza vaccine recommend lung transplant patient , study show single intramuscular ( i.m . ) dose poor immunogenicity . There study define effect intradermal dos population . We plan study immunogenicity two-dose regimen influenza vaccine 50 lung transplant patient 2006-2007 season . After initial i.m . injection , second dose give intradermally 4 week later . Antibody titer evaluate standard hemagglutination inhibition assay . We hypothesize second dose intradermally significantly increase proportion vaccine responder .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Lung transplant recipient great 3 month posttransplant Â· Egg allergy Previous lifethreatening reaction influenza vaccine ( ie Guillain Barre Syndrome ) On anticoagulant warfarin precludes intramuscular injection Ongoing therapy rejection Febrile illness past two week Unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Intradermal</keyword>
	<keyword>Lung transplantation</keyword>
</DOC>